{"transactions":[{"id":4317,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10002,"kind":"person","name":"Manke Isaac","position":1,"cik":"0001622769","reported_name":"Manke Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:03:30.000Z","date":"2026-09-02","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of options was repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":50000,"derivative":{"exercise_price":0.032,"exercise_date":"2024-01-08","expiration_date":"2034-01-07","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-26-105491","document":"tm2624769-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1622769/000110465926105491/tm2624769-3_4seq1.xml","form_type":"4"}},{"id":4316,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10002,"kind":"person","name":"Manke Isaac","position":1,"cik":"0001622769","reported_name":"Manke Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:03:30.000Z","date":"2026-09-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of options was repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":0,"derivative":{"exercise_price":0.062,"exercise_date":"2024-01-08","expiration_date":"2034-01-07","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-26-105491","document":"tm2624769-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1622769/000110465926105491/tm2624769-3_4seq1.xml","form_type":"4"}},{"id":4315,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10002,"kind":"person","name":"Manke Isaac","position":1,"cik":"0001622769","reported_name":"Manke Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-04T20:03:30.000Z","date":"2026-09-02","kind":"grant","planned":false,"acquired":true,"shares":219561,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents 219,561 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 128,238 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 91,323 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents 219,561 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 128,238 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 91,323 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."}],"balance_after":219561,"source":{"system":"sec-edgar","filing":"0001104659-26-105491","document":"tm2624769-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1622769/000110465926105491/tm2624769-3_4seq1.xml","form_type":"4"}},{"id":4314,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10002,"kind":"person","name":"Manke Isaac","position":1,"cik":"0001622769","reported_name":"Manke Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-04T20:03:30.000Z","date":"2026-09-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":219561,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents 219,561 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 128,238 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 91,323 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents 219,561 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 128,238 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 91,323 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-105491","document":"tm2624769-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1622769/000110465926105491/tm2624769-3_4seq1.xml","form_type":"4"}},{"id":690672,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":10002,"kind":"person","name":"Manke Isaac","position":1,"cik":"0001622769","reported_name":"Manke Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-11T20:39:03.000Z","date":"2026-08-07","kind":"grant","planned":false,"acquired":true,"shares":15300,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on August 7, 2026 (the \"Effective Date\"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a \"Retention Period\" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The \"Retention Period\" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/36th of the shares subject to the option vested on November 4, 2024 and 1/36th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":15300,"derivative":{"exercise_price":4.14,"expiration_date":"2034-10-03","underlying":"Class A Common Stock","underlying_shares":15300},"source":{"system":"sec-edgar","filing":"0001622769-26-000002","document":"form4-08112026_080858.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1622769/000162276926000002/form4-08112026_080858.xml","form_type":"4"}},{"id":690671,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":10002,"kind":"person","name":"Manke Isaac","position":1,"cik":"0001622769","reported_name":"Manke Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-11T20:39:03.000Z","date":"2026-08-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15300,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on August 7, 2026 (the \"Effective Date\"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a \"Retention Period\" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The \"Retention Period\" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/36th of the shares subject to the option vested on November 4, 2024 and 1/36th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":0,"derivative":{"exercise_price":18.2,"expiration_date":"2034-10-03","underlying":"Class A Common Stock","underlying_shares":15300},"source":{"system":"sec-edgar","filing":"0001622769-26-000002","document":"form4-08112026_080858.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1622769/000162276926000002/form4-08112026_080858.xml","form_type":"4"}},{"id":690670,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":10002,"kind":"person","name":"Manke Isaac","position":1,"cik":"0001622769","reported_name":"Manke Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-11T20:39:03.000Z","date":"2026-08-07","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the option shall vest on February 24, 2027 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":300000,"derivative":{"exercise_price":4.14,"expiration_date":"2036-08-06","underlying":"Class A Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001622769-26-000002","document":"form4-08112026_080858.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1622769/000162276926000002/form4-08112026_080858.xml","form_type":"4"}},{"id":705178,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":10002,"kind":"person","name":"Manke Isaac","position":1,"cik":"0001622769","reported_name":"Manke Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-22T00:25:05.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":10826,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026."}],"balance_after":10826,"derivative":{"exercise_price":12.64,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":10826},"source":{"system":"sec-edgar","filing":"0001193125-26-310969","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1622769/000119312526310969/ownership.xml","form_type":"4/A","original_submission_date":"2026-06-16"}},{"id":717898,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":10002,"kind":"person","name":"Manke Isaac","position":1,"cik":"0001622769","reported_name":"Manke Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T20:30:19.000Z","date":"2026-06-30","kind":"exercise","planned":false,"acquired":false,"shares":53521,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":2.8,"expiration_date":"2035-10-22","underlying":"Common Stock","underlying_shares":53521},"source":{"system":"sec-edgar","filing":"0001193125-26-294694","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1622769/000119312526294694/ownership.xml","form_type":"4"}},{"id":717897,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":10002,"kind":"person","name":"Manke Isaac","position":1,"cik":"0001622769","reported_name":"Manke Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-02T20:30:19.000Z","date":"2026-06-30","kind":"exercise","planned":false,"acquired":true,"shares":53521,"price":2.8,"value":149858.8,"ownership":{"direct":true},"balance_after":53521,"source":{"system":"sec-edgar","filing":"0001193125-26-294694","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1622769/000119312526294694/ownership.xml","form_type":"4"}},{"id":736132,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":10002,"kind":"person","name":"Manke Isaac","position":1,"cik":"0001622769","reported_name":"Manke Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-16T20:30:37.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":9810,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":9810,"derivative":{"exercise_price":12.64,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":9810},"source":{"system":"sec-edgar","filing":"0001193125-26-272698","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1622769/000119312526272698/ownership.xml","form_type":"4"}},{"id":955174,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":10002,"kind":"person","name":"Manke Isaac","position":1,"cik":"0001622769","reported_name":"Manke Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2026-01-02T21:10:23.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":true,"shares":5258,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock. The RSUs were granted to the Reporting Person in lieu of a quarterly cash retainer, at the election of the Reporting Person, under the Issuer's Outside Director Compensation Policy."}],"balance_after":20583,"source":{"system":"sec-edgar","filing":"0001622769-26-000001","document":"form4-01022026_090120.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1622769/000162276926000001/form4-01022026_090120.xml","form_type":"4"}},{"id":1013230,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":10002,"kind":"person","name":"Manke Isaac","position":1,"cik":"0001622769","reported_name":"Manke Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-28T01:26:15.000Z","date":"2025-10-23","kind":"grant","planned":false,"acquired":true,"shares":53521,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) October 23, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":53521,"derivative":{"exercise_price":2.8,"expiration_date":"2035-10-22","underlying":"Common Stock","underlying_shares":53521},"source":{"system":"sec-edgar","filing":"0001193125-25-251993","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1622769/000119312525251993/ownership.xml","form_type":"4"}},{"id":1027171,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":10002,"kind":"person","name":"Manke Isaac","position":1,"cik":"0001622769","reported_name":"Manke Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2025-10-02T20:16:25.000Z","date":"2025-09-30","kind":"grant","planned":false,"acquired":true,"shares":5545,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock. The RSUs were granted to the Reporting Person in lieu of a quarterly cash retainer, at the election of the Reporting Person, under the Issuer's Outside Director Compensation Policy."}],"balance_after":15325,"source":{"system":"sec-edgar","filing":"0001622769-25-000003","document":"form4-10022025_081020.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1622769/000162276925000003/form4-10022025_081020.xml","form_type":"4"}},{"id":1095129,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":10002,"kind":"person","name":"Manke Isaac","position":1,"cik":"0001622769","reported_name":"Manke Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2025-07-02T20:26:16.000Z","date":"2025-06-30","kind":"grant","planned":false,"acquired":true,"shares":6311,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock. The RSUs were granted to the Reporting Person in lieu of a quarterly cash retainer, at the election of the Reporting Person, under the Issuer's Outside Director Compensation Policy."}],"balance_after":9780,"source":{"system":"sec-edgar","filing":"0001415889-25-019052","document":"form4-07022025_080710.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1622769/000141588925019052/form4-07022025_080710.xml","form_type":"4"}},{"id":1129210,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":10002,"kind":"person","name":"Manke Isaac","position":1,"cik":"0001622769","reported_name":"Manke Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-30T20:53:31.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":7650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option will vest on the earlier of May 28, 2026 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date."}],"balance_after":7650,"derivative":{"exercise_price":2.44,"expiration_date":"2035-05-27","underlying":"Class A Common Stock","underlying_shares":7650},"source":{"system":"sec-edgar","filing":"0001415889-25-015018","document":"form4-05302025_080518.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1622769/000141588925015018/form4-05302025_080518.xml","form_type":"4"}},{"id":1183361,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":10002,"kind":"person","name":"Manke Isaac","position":1,"cik":"0001622769","reported_name":"Manke Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2025-04-02T20:37:48.000Z","date":"2025-03-31","kind":"grant","planned":false,"acquired":true,"shares":3469,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock. The RSUs were granted to the Reporting Person in lieu of a quarterly cash retainer, at the election of the Reporting Person, under the Issuer's Outside Director Compensation Policy."}],"balance_after":3469,"source":{"system":"sec-edgar","filing":"0001415889-25-009659","document":"form4-04022025_080441.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1622769/000141588925009659/form4-04022025_080441.xml","form_type":"4"}},{"id":1240671,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":10002,"kind":"person","name":"Manke Isaac","position":1,"cik":"0001622769","reported_name":"Manke Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-27T11:05:43.000Z","date":"2025-02-24","kind":"grant","planned":false,"acquired":true,"shares":19008,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 24, 2025, the Issuer's board of directors approved an option repricing (\"Repricing Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the \"2017 Plan\") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the \"2024 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":19008,"derivative":{"exercise_price":2.53,"expiration_date":"2035-01-14","underlying":"Common Stock","underlying_shares":19008},"source":{"system":"sec-edgar","filing":"0000950170-25-028306","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1622769/000095017025028306/ownership.xml","form_type":"4"}},{"id":1240670,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":10002,"kind":"person","name":"Manke Isaac","position":1,"cik":"0001622769","reported_name":"Manke Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-27T11:05:43.000Z","date":"2025-02-24","kind":"disposition_to_issuer","planned":false,"acquired":true,"shares":19008,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 24, 2025, the Issuer's board of directors approved an option repricing (\"Repricing Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the \"2017 Plan\") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the \"2024 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":3.2,"expiration_date":"2035-01-14","underlying":"Common Stock","underlying_shares":19008},"source":{"system":"sec-edgar","filing":"0000950170-25-028306","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1622769/000095017025028306/ownership.xml","form_type":"4"}},{"id":1240669,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":10002,"kind":"person","name":"Manke Isaac","position":1,"cik":"0001622769","reported_name":"Manke Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-27T11:05:43.000Z","date":"2025-01-15","kind":"grant","planned":false,"acquired":true,"shares":19008,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"This option was granted to the Reporting Person, a director of the Issuer pursuant to the 2024 Plan and pursuant to the Issuer's non-employee director compensation policy. This option represents the Reporting Person's election to receive stock options in lieu of cash retainer fees Due to administrative oversight this option award initially was not reported."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted to the Reporting Person, a director of the Issuer pursuant to the 2024 Plan and pursuant to the Issuer's non-employee director compensation policy. This option represents the Reporting Person's election to receive stock options in lieu of cash retainer fees Due to administrative oversight this option award initially was not reported."}],"balance_after":19008,"derivative":{"exercise_price":3.2,"expiration_date":"2035-01-14","underlying":"Common Stock","underlying_shares":19008},"source":{"system":"sec-edgar","filing":"0000950170-25-028306","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1622769/000095017025028306/ownership.xml","form_type":"4"}},{"id":1240668,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":10002,"kind":"person","name":"Manke Isaac","position":1,"cik":"0001622769","reported_name":"Manke Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-27T11:05:43.000Z","date":"2025-02-24","kind":"grant","planned":false,"acquired":true,"shares":2627,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 24, 2025, the Issuer's board of directors approved an option repricing (\"Repricing Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 24, 2025, the Issuer's board of directors approved an option repricing (\"Repricing Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the \"2017 Plan\") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the \"2024 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":2627,"derivative":{"exercise_price":2.54,"expiration_date":"2034-03-31","underlying":"Common Stock","underlying_shares":2627},"source":{"system":"sec-edgar","filing":"0000950170-25-028306","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1622769/000095017025028306/ownership.xml","form_type":"4"}},{"id":1240667,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":10002,"kind":"person","name":"Manke Isaac","position":1,"cik":"0001622769","reported_name":"Manke Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-27T11:05:43.000Z","date":"2025-02-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2627,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 24, 2025, the Issuer's board of directors approved an option repricing (\"Repricing Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 24, 2025, the Issuer's board of directors approved an option repricing (\"Repricing Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the \"2017 Plan\") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the \"2024 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":18,"expiration_date":"2034-03-31","underlying":"Common Stock","underlying_shares":2627},"source":{"system":"sec-edgar","filing":"0000950170-25-028306","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1622769/000095017025028306/ownership.xml","form_type":"4"}},{"id":1240666,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":10002,"kind":"person","name":"Manke Isaac","position":1,"cik":"0001622769","reported_name":"Manke Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-27T11:05:43.000Z","date":"2025-02-24","kind":"grant","planned":false,"acquired":true,"shares":12767,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 24, 2025, the Issuer's board of directors approved an option repricing (\"Repricing Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 24, 2025, the Issuer's board of directors approved an option repricing (\"Repricing Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the \"2017 Plan\") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the \"2024 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":12767,"derivative":{"exercise_price":2.54,"expiration_date":"2034-03-24","underlying":"Common Stock","underlying_shares":12767},"source":{"system":"sec-edgar","filing":"0000950170-25-028306","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1622769/000095017025028306/ownership.xml","form_type":"4"}},{"id":1240665,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":10002,"kind":"person","name":"Manke Isaac","position":1,"cik":"0001622769","reported_name":"Manke Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-27T11:05:43.000Z","date":"2025-02-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12767,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 24, 2025, the Issuer's board of directors approved an option repricing (\"Repricing Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 24, 2025, the Issuer's board of directors approved an option repricing (\"Repricing Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the \"2017 Plan\") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the \"2024 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":16.82,"expiration_date":"2034-03-24","underlying":"Common Stock","underlying_shares":12767},"source":{"system":"sec-edgar","filing":"0000950170-25-028306","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1622769/000095017025028306/ownership.xml","form_type":"4"}},{"id":1389278,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":10002,"kind":"person","name":"Manke Isaac","position":1,"cik":"0001622769","reported_name":"Manke Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-08T23:27:36.000Z","date":"2024-10-04","kind":"grant","planned":false,"acquired":true,"shares":15300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option shall vest on November 4, 2024 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":15300,"derivative":{"exercise_price":18.2,"expiration_date":"2034-10-03","underlying":"Class A Common Stock","underlying_shares":15300},"source":{"system":"sec-edgar","filing":"0001415889-24-024919","document":"form4-10082024_111032.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1622769/000141588924024919/form4-10082024_111032.xml","form_type":"4"}},{"id":1397873,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":10002,"kind":"person","name":"Manke Isaac","position":1,"cik":"0001622769","reported_name":"Manke Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-30T10:01:05.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":2627,"price":13.42,"value":35254.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This option was granted in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive equity in lieu of cash compensation for services as a non-employee director of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option vest in three equal quarterly installments on each of June 30, 2024, September 30, 2024 and December 31, 2024."}],"balance_after":2627,"derivative":{"exercise_price":18,"expiration_date":"2034-03-31","underlying":"Common Stock","underlying_shares":2627},"source":{"system":"sec-edgar","filing":"0000950170-24-110152","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1622769/000095017024110152/ownership.xml","form_type":"4"}},{"id":1559486,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":10002,"kind":"person","name":"Manke Isaac","position":1,"cik":"0001622769","reported_name":"Manke Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-27T21:42:01.000Z","date":"2024-03-25","kind":"grant","planned":false,"acquired":true,"shares":12767,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the shares underlying this option shall vest and become exercisable on March 25, 2025, with the remainder vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":12767,"derivative":{"exercise_price":16.82,"expiration_date":"2034-03-24","underlying":"Common Stock","underlying_shares":12767},"source":{"system":"sec-edgar","filing":"0000950170-24-037403","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1622769/000095017024037403/ownership.xml","form_type":"4"}}]}